Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jade Biosciences, Inc. (JBIO : NSDQ)

• Company Description    Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $15.43 Daily Weekly Monthly 20 Day Moving Average: 391,253 shares Shares Outstanding: 49.31 (millions) Market Capitalization: $760.92 (millions) Beta: 1.02 52 Week High: $17.71 52 Week Low: $2.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.43% 24.65% 12 Week 64.15% 61.50% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - Waltham,MA 02453 USA ph: 781-312-3013 fax: - info@jadebiosciences.com https://jadebiosciences.com

• General Corporate Information    Officers Timothy P. Noyes - Chief Executive Officer and Director George A. Eldridge - Chief Financial Officer Habib Dable - Director Allison Dorval - Director David Grayzel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 008064206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 49.31 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.02 Market Capitalization: $760.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.81 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 97.56% vs. Previous Quarter: 44.19% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -49.03 06/30/25 - -51.96 ROA 12/31/25 - - 09/30/25 - -44.67 06/30/25 - -47.65 Current Ratio 12/31/25 - - 09/30/25 - 9.01 06/30/25 - 10.31 Quick Ratio 12/31/25 - - 09/30/25 - 9.01 06/30/25 - 10.31 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 5.50 06/30/25 - 6.18 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©